| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Defibrotide |
| Brand | Defitelio® |
| Indication | Indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy |
| Assessment Process | |
| Rapid review commissioned | 12/05/2014 |
| Rapid review completed | 10/07/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.